Dr. Jamie Chaft says neoadjuvant chemoimmunotherapy offers thoracic oncologists an opportunity to cure more patients. Read more
Dr. Mary O’Brien and colleagues say decision making around operable cases is becoming increasingly complex, making a multidisciplinary approach imperative. Read more
In Part 2 of their exploration of artificial intelligence, Dr. Raymond Mak and Fridolin Haugg reflect on the possibilities ahead for the diagnosis and treatment of lung cancer. Read more
Dr. Barbara Andersen’s research has shown depression severity is associated with prognostically poor inflammation in patients with non-small cell lung cancer. Read more
Dr. Raymond Mak and Fridolin Haugg delve into the artificial intelligence discussion with an overview of AI basics and a look at how AI is already influencing the lung cancer field. Read more
When life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more. Read more
Like it or not, AI will be part the diagnostic and therapeutic landscape, and it is incumbent on clinicians to understand its implications, limitations, and benefits, ILCN editors say. Read more
Investigator Ticiana Leal, MD, said the the phase III LUNAR study met its primary endpoint and demonstrated a statistically significant 3-month improvement in median overall survival versus the standard of care. Read more
Dr. Sharyn Katz and colleagues summarize key recommendations for improving imaging quality in malignant pleural mesothelioma. Read more
Dr. Roy Herbst said the results reinforce adjuvant osimertinib as the standard of care for patients with resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer and highlight the importance of early biomarker testing. Read more